Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Gains from Sales and Divestitures (2019 - 2025)

Cytosorbents (CTSO) has disclosed Gains from Sales and Divestitures for 7 consecutive years, with $35000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gains from Sales and Divestitures rose 6.06% year-over-year to $35000.0, compared with a TTM value of $35000.0 through Sep 2025, up 6.06%, and an annual FY2024 reading of $297169.0, up 375.47% over the prior year.
  • Gains from Sales and Divestitures was $35000.0 for Q3 2025 at Cytosorbents, down from $139000.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $297169.0 in Q4 2024 and bottomed at $20000.0 in Q2 2024.
  • Average Gains from Sales and Divestitures over 5 years is $101224.8, with a median of $62500.0 recorded in 2023.
  • The sharpest move saw Gains from Sales and Divestitures plummeted 83.83% in 2024, then soared 595.0% in 2025.
  • Year by year, Gains from Sales and Divestitures stood at $196525.0 in 2021, then crashed by 77.1% to $45000.0 in 2022, then skyrocketed by 38.89% to $62500.0 in 2023, then skyrocketed by 375.47% to $297169.0 in 2024, then plummeted by 88.22% to $35000.0 in 2025.
  • Business Quant data shows Gains from Sales and Divestitures for CTSO at $35000.0 in Q3 2025, $139000.0 in Q2 2025, and $65000.0 in Q1 2025.